Mobemid (Moclobemide)

Moclobemide is indicated for depressive disorders that involve monoamine neurotransmitter dysregulation.

• Major depressive disorder: alleviates depressive symptoms and improves mood in adults.
• Depressive episodes: reduces severity of episodic depressive periods associated with mood disorders.

• Moclobemide reversibly binds to the flavin adenine dinucleotide (FAD) site of monoamine oxidase A, inhibiting its enzymatic activity. This inhibition prevents the breakdown of serotonin, norepinephrine, and dopamine, thereby increasing their synaptic concentrations and enhancing neurotransmission in brain regions implicated in mood regulation.

Moclobemide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: intermittent tension‑type pain.
• Dizziness: sensation of light‑headedness, especially on standing.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Hypertensive crisis: sudden, severe elevation of blood pressure, often triggered by tyramine‑rich foods.
• Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities when combined with other serotonergic agents.
• Severe liver injury: jaundice, elevated transaminases, or hepatic failure.

Before initiating therapy with Moclobemide, clinicians should consider several safety measures.

• Liver function assessment: evaluate baseline hepatic enzymes and monitor periodically.
• Blood pressure monitoring: check for hypertension, especially after dietary tyramine exposure.
• Dietary restrictions: advise patients to avoid high‑tyramine foods such as aged cheeses and cured meats.
• Concomitant serotonergic drugs: review all antidepressants, triptans, and linezolid to prevent serotonin excess.
• Suicidal ideation evaluation: monitor mood changes, particularly during early treatment phases.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Moclobemide can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

• Other MAO inhibitors: combined inhibition can precipitate hypertensive emergencies.
• Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): risk of serotonin syndrome.
• Meperidine or other opioid analgesics: may cause severe hypertension.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding risk.
• Antihypertensive agents: potential for additive blood pressure lowering effects.